Business Description
Medigen Biotechnology Corp
ISIN : TW0003176004
Total Employee Number:
67Description
Medigen Biotechnology Corp is engaged in the research and development of new drugs and vaccines, cytotherapy, nucleic acid testing, and the production and sales of generic drugs, aesthetic medicine products and vaccine-related products. Its segments are the Nucleic acid department, the New drug and vaccine research and development segment, the Cytotherapy department, and the Generic drug, aesthetic medicine product and dietary supplement segment: responsible for production and sales and relevant services of western medicine, aesthetic medicine product, and dietary supplement. The majority of revenue is derived from generic drugs, aesthetic medicine products, and the dietary supplement segment. Geographically, it operates in Taiwan, China, and Other countries with revenue from Taiwan.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 2.65 | |||||
Equity-to-Asset | 0.25 | |||||
Debt-to-Equity | 0.62 | |||||
Debt-to-EBITDA | -48.03 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 2.76 | |||||
Beneish M-Score | -2.64 | |||||
WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 14.4 | |||||
3-Year EBITDA Growth Rate | 77.1 | |||||
3-Year EPS without NRI Growth Rate | 45.8 | |||||
3-Year FCF Growth Rate | 70.6 | |||||
3-Year Book Growth Rate | -10.9 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 42.77 | |||||
9-Day RSI | 49.52 | |||||
14-Day RSI | 52.01 | |||||
3-1 Month Momentum % | 6.72 | |||||
6-1 Month Momentum % | 1.83 | |||||
12-1 Month Momentum % | 10.07 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.68 | |||||
Quick Ratio | 3.9 | |||||
Cash Ratio | 3.39 | |||||
Days Inventory | 351.4 | |||||
Days Sales Outstanding | 50.36 | |||||
Days Payable | 35.19 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Shareholder Yield % | 9.95 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 57.19 | |||||
Operating Margin % | -6.64 | |||||
Net Margin % | -6.88 | |||||
EBITDA Margin % | -1.25 | |||||
FCF Margin % | -2.08 | |||||
OCF Margin % | 2.56 | |||||
ROE % | -6.68 | |||||
ROA % | -1.68 | |||||
ROIC % | -2.88 | |||||
3-Year ROIIC % | -160.79 | |||||
ROC (Joel Greenblatt) % | -8.14 | |||||
ROCE % | -3.44 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 3.12 | |||||
PB Ratio | 3.17 | |||||
Price-to-Tangible-Book | 3.39 | |||||
Price-to-Operating-Cash-Flow | 120.41 | |||||
EV-to-EBIT | -33.37 | |||||
EV-to-EBITDA | -328.88 | |||||
EV-to-Revenue | 4.13 | |||||
EV-to-FCF | -210.27 | |||||
Price-to-GF-Value | 0.71 | |||||
Price-to-Median-PS-Value | 0.27 | |||||
Earnings Yield (Greenblatt) % | -3 | |||||
FCF Yield % | -0.67 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Medigen Biotechnology Corp Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil NT$) | 1,582.503 | ||
| EPS (TTM) (NT$) | -0.785 | ||
| Beta | 0.3347 | ||
| 3-Year Sharpe Ratio | 0.05 | ||
| 3-Year Sortino Ratio | 0.11 | ||
| Volatility % | 14.04 | ||
| 14-Day RSI | 52.01 | ||
| 14-Day ATR (NT$) | 1.448199 | ||
| 20-Day SMA (NT$) | 34.8925 | ||
| 12-1 Month Momentum % | 10.07 | ||
| 52-Week Range (NT$) | 28 - 43.6 | ||
| Shares Outstanding (Mil) | 139.31 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Medigen Biotechnology Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Medigen Biotechnology Corp Stock Events
| Event | Date | Price (NT$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Medigen Biotechnology Corp Frequently Asked Questions
What is Medigen Biotechnology Corp(ROCO:3176)'s stock price today?
The current price of ROCO:3176 is NT$35.40. The 52 week high of ROCO:3176 is NT$43.60 and 52 week low is NT$28.00.
When is next earnings date of Medigen Biotechnology Corp(ROCO:3176)?
The next earnings date of Medigen Biotechnology Corp(ROCO:3176) is .
Does Medigen Biotechnology Corp(ROCO:3176) pay dividends? If so, how much?
Medigen Biotechnology Corp(ROCO:3176) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Medigen Biotechnology Corp
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers